Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Latvia and Baylor College Of Medicine!!
BCG epidemiology supports its protection against COVID-19? A word of caution
Reka Szigeti 1, Domos Kellermayer 2, Giedrius Trakimas 3 4, Richard Kellermayer 5 6 7
Affiliations collapse
Affiliations
1Department of Pathology & Genomic Medicine, Houston Methodist Hospital, Houston, Texas, United States of America.
2University of Houston, Houston, Texas, United States of America.
3Institute of Biosciences, Vilnius University, Vilnius, Latvia.
4Institute of Life Sciences and Technology, Daugavpils University, Daugavpils, Latvia.
5Section of Pediatric Gastroenterology, Texas Children's Hospital, Houston, Texas, United States of America.
6Baylor College of Medicine, Houston, Texas, United States of America.
7USDA/ARS Children's Nutrition Research Center, Houston, Texas, United States of America.
https://pubmed.ncbi.nlm.nih.gov/33027297/
JCI Insight - Welcome
insight.jci.org › tags › 41
Jan 26, 2021 · Neutralizing Abs against heterologous influenza viruses were undetectable. Head-specific B cells from draining lymph nodes exhibited germinal center markers, while stem-specific B cells found in the spleen and peripheral blood did not.
Effective SARS-CoV-2 vaccines are urgently needed. While most vaccine strategies have focused on systemic immunization, here we compared the protective efficacy of two adjuvanted subunit vaccines with spike protein S1: an intramuscular (IM)- primed /boosted vaccine and an IM-primed/intranasal (IN)-boosted mucosal vaccine, in rhesus macaques. The IM-alum-only vaccine induced robust binding and neutralizing antibody and persistent cellular immunity systemically and mucosally, while IN boosting with nanoparticles including IL-15 and TLR agonists elicited weaker T-cell and antibody responses, but higher dimeric IgA and IFNa. Nevertheless, following SARS-CoV-2 challenge, neither group showed detectable subgenomic RNA in upper or lower respiratory tracts vs naïve controls, indicating full protection against viral replication. Though mucosal and systemic protective mechanisms may differ, results demonstrate both vaccines can protect against respiratory SARS-CoV-2 exposure. The mucosal vaccine was safe after multiple doses and cleared the input virus more efficiently in the nasal cavity, and thus may act as a potent complementary reinforcing boost for conventional systemic vaccines to provide overall better protection.
https://insight.jci.org/articles/view/148494
Potential for developing a SARS-CoV receptor-binding domain ...
pubmed.ncbi.nlm.nih.gov › 32298218
This information is relevant and supports the possibility of developing a heterologous SARS-CoV RBD vaccine against COVID-19, especially due to the finding that the overall high amino acid similarity (82%) between SARS-CoV and SARS-CoV-2 spike and RBD domains is not reflected in RBM amino acid similarity (59%).
Author: Wen-Hsiang Chen, Peter J Hotez, Maria Elena Bottazzi
Cited by: 45
https://pubmed.ncbi.nlm.nih.gov/32298218/
Positive association between COVID-19 deaths and influenza ...
peerj.com › articles › 10112
Given that heterologous immunity could improve protective immunity against COVID-19 and, thus, prevent COVID-19 deaths in the future, the aim in this study was to analyze the possible association between COVID-19 deaths and the IVR in elderly people worldwide.
The term “heterologous immunity” is applied when an infection by one pathogen can induce and/or alter the immune response against another unrelated pathogen. Heterologous immunity can improve or decrease protective immunity against a given pathogen, and/or cause severe immunopathology or tolerance to self-antigens. Heterologous immunity can also result in non-specific effects (also called “heterologous effects”) of vaccines which affect unrelated infections and diseases, such as extending the protective outcomes of vaccinations
https://peerj.com/articles/10112/
J. Miller, D.V.M., Ph.D.
Infectious Diseases Unit
Core Scientist
Professor
Department of Pathology, Microbiology, & Immunology School of Veterinary Medicine
HIV Transmission
Because of physiological and immunological similarities, macaques offer opportunities to investigate host-pathogen interactions with direct relevance to infection and immunity in humans. SIV or SHIV infection of susceptible macaques serves as a model of HIV transmission and analysis of antiviral host responses at mucosal surfaces. In addition, the effects of age on efficacy of vaccine induced immunity can be determined through challenge with the corresponding pathogen.
https://cnprc.ucdavis.edu/chris-miller/
WOW Nice Find! Recent results obtained from a smaller scale macaque trial in China on Mymetics’ HIV vaccine demonstrated 100% protection in one arm of the study against multiple intra-vaginal challenges with heterologous live virus, while the placebo group became fully infected. These results are unprecedented for this type of HIV vaccine study. The vaccine is also currently in a Phase I clinical
https://www.sec.gov/Archives/edgar/data/927761/000095012310085762/l40686exv99w1.htm
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
https://pubmed.ncbi.nlm.nih.gov/32999467/
Let's see if Kemper's can pull some good news out of his magic hat!! Not his A**
https://media.istockphoto.com/vectors/top-hat-with-wand-and-stars-vector-id121397886?k=6&m=121397886&s=612x612&w=0&h=EOCfVOaXEIBcRO_GK7s2vL61fxKpLXZ89xRtgkvcbZs=
Mymetics to Advance Preclinical Studies for Virosome? LOL
WHEN IS MYMETICS EVER GOING TO GET OUT OF PRECLINICAL ON ANYTHING?
I push KEMPER'S off Building :)
https://thumbs.dreamstime.com/z/jumping-off-building-22741967.jpg
Allergen-Specific Immunotherapy of Allergy and Asthma
www.medscape.com › viewarticle › 588101_11
F Spertini, C Reymond and A Leimgruber are cofounders and shareholders of Anergis SA, a start-up from the University of Lausanne, Switzerland, active in the field of allergy immunotherapy
Annette Leimgruber did not know this person was also cofounder of Anergis
Please be a moderator and fill that last position with MYMX :)
Well, If it's not the Mountain Man!! :)
https://wrathofzombie.files.wordpress.com/2013/04/mountain-man.jpg
Webinar: Is Lipid Based Formulation Best for Your Molecule? Insights from exclusive survey on strategies for poorly soluble molecules
Sponsored by: Catalent Pharma Solutions
https://www.business-review-webinars.com/webinar/Pharma/Is_Lipid_Based_Formulation_Best_for_Your_MoleculeInsights_from_exclusive_survey_on_strategies_for_poorly_soluble_molecules-qxpr9zWm
https://japan.catalent.com/news-events/news/Catalent-Experts-to-Discuss-Oral-Peptide-Delivery-and-Advanced-Modelling-to-Optimize-Formulation-at-Upcoming-Controlled-Release-Society-Conference
https://japan.catalent.com/news-events/events/TIDES-Oligonucleotide-and-Peptide-Therapeutics
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159359868
Oral Delivery of Macromolecule Drugs for Localized Treatments of Gut Diseases
Dr. Claus-Michael Lehr
https://crotraining.co.uk/webinars/oral-delivery-of-macromolecule-drugs-for-localized-treatments-of-gut-diseases/
A universal coronavirus vaccine
Wayne C. Koff1?, Seth F. Berkley2?
1Wayne C. Koff is chief executive officer of the Human Vaccines Project, New York, NY, USA.
2Seth F. Berkley is chief executive officer of Gavi, The Vaccine Alliance, Geneva, Switzerland.
wkoff@humanvaccinesproject.org
sberkley@gavi.org
Hide authors and affiliations
Science 19 Feb 2021:
Vol. 371, Issue 6531, pp. 759
DOI: 10.1126/science.abh0447
https://science.sciencemag.org/content/371/6531/759.full
CANADA
Researchers racing to develop one vaccine for all coronaviruses
A similar effort was underway following the SARS outbreak of 2003, when researcher Maria Elena Bottazzi at the Baylor College of medicine started working on a pan-coronavirus vaccine. In 2016 her team applied for financial support to develop a vaccine but did not receive it.
In fact, her team even lost funding for a SARS vaccine it had been developing which showed promising results in mice but without the financial support they were not able to transition it to a clinical setting.
https://globalnews.ca/news/7747074/covid-universal-coronavirus-vaccine-research/
Ultrapotent COVID-19 vaccine candidate designed via computer ...
www.eurekalert.org › pub_releases › 2020-11
The lead authors of this paper are Alexandra Walls, a research scientist in the laboratory of David Veesler, ... Bill & Melinda Gates Foundation, Defense Threat Reduction Agency, Pew Biomedical
"I am delighted that our studies of antibody responses to coronaviruses led to the design of this promising vaccine candidate," said Veesler, who spearheaded the concept of a multivalent receptor-binding domain-based vaccine.
https://www.eurekalert.org/pub_releases/2020-11/uowh-ucv110220.php
https://www.ipd.uw.edu/2020/10/design-of-an-ultrapotent-covid-19-vaccine-candidate/
https://www.nature.com/articles/s41598-021-83730-y
Very Nice find Friend! :)
Deep Mutational Scanning of SARS-CoV-2 Receptor
Binding Domain Reveals Constraints on Folding and
ACE2 Binding
Authors
Tyler N. Starr, Allison J. Greaney,
Sarah K. Hilton, ..., Neil P. King,
David Veesler, Jesse D. Bloom
https://www.cell.com/cell/pdf/S0092-8674(20)31003-5.pdf
UPPERTON / 11th March 2021 - Nasal Delivery of Therapeutics and Vaccines
Nasal vaccination is not new, MedImmue’s FluMist®, approved in 2003, delivers an annual influenza vaccine intranasally and other groups such as Mymetics (Switzerland) have reported promising results with nasally administered HIV vaccines.
https://www.upperton.com/11th-march-2021-nasal-delivery-of-therapeutics-and-vaccines/
You could be right my friend!! :)
New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.
Amacker M1, Smardon C2, Mason L3, Sorrell J3, Jeffery K3, Adler M4, Bhoelan F5, Belova O5, Spengler M4, Punnamoottil B4, Schwaller M6, Bonduelle O7, Combadière B7, Stegmann T5, Naylor A3, Johnson R3, Wong D2, Fleury S1
https://europepmc.org/article/MED/33580048
Go click on this takes you to Baylor College of Medicine and Iran paper
Citations & impact
Baylor
Recombinant protein vaccines, a proven approach against coronavirus pandemics.
Pollet J, Chen WH, Strych U
Adv Drug Deliv Rev, 170:71-82, 07 Jan 2021
Cited by: 2 articles | PMID: 33421475 | PMCID: PMC7788321
Iran
Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.
Asadi K, Gholami A
Int J Biol Macromol, 182:648-658, 15 Apr 2021
Cited by: 0 articles | PMID: 33862071 | PMCID: PMC8049750
All FUNDING BY THE SWISS GOV and EU
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priorioty Industrial Leadership | H2020 Industrial Leadership - Leadership in Enabling and Industrial Technologies | H2020 LEIT Nanotechnologies (H2020 Leadership in Enabling and Industrial Technologies - Nanotechnologies) (1)?
Eidgenössischen Departement für Wirtschaft, Bildung und Forschung (Federal Department of Economic Affairs, Education and Research, Switzerland) (1)?
Results for Laura Mason (Upperton)
https://europepmc.org/search?query=AUTHORID%3A0000-0003-3895-8532
Laura Mason at UPPERTON
Director of Business Operations
Dr Laura Mason joined Upperton in 2016 as a Project Scientist, quickly progressing to the role of Business Operations Director. Laura has previous experience within solid oral dosage form development having completed her PhD in the School of Pharmacy at the University of Nottingham, and her Pharmacy Pre-Registration Year at Merck Sharp and Dohme and Guy’s & St Thomas’ Hospital. Laura is a UK Registered Pharmacist, the current treasurer of the UKICRS and a member of several pharmaceutical societies. Laura supports the introduction and co-ordination of the company’s R&D projects.
https://www.upperton.com/about-us/
Upperton 29th April 2021 - Formulation Options in Nasal Drug Delivery
https://www.upperton.com/29th-april-2021-formulation-options-in-nasal-drug-delivery/
WAR FACES COMING TO YOU MR. K / GET IT DONE!!
https://img.thedailybeast.com/image/upload/v1501967723/170804-Troy-Warner-Klemper-tease_zkmnlf.jpg
Mr. Kemper's and company better have something here or they will be washing car windows with newspapers! Let's see it!!
https://www.thoughtco.com/thmb/ts8ZfDn5ZYFnk8UAXUyyETD99n4=/768x0/filters:no_upscale():max_bytes(150000):strip_icc()/crumpled-newsprint--paper-465762400-5b0765fa0e23d90036f6b7b4.jpg
Yep! Your Right!! As of April 5th 2021
Allergic Rhinitis Market to Eyewitness Potential Growth till 2027 | Players – Anergis, HAL Allergy Group, Merck. April 5, 2021
https://ksusentinel.com/2021/04/05/allergic-rhinitis-market-to-eyewitness-potential-growth-till-2027-players-anergis-hal-allergy-group-merck/
VIROSOME TAGGS
STRUCTURAL APPROACHES TO HIV-1 IMMUNOGEN DESIGN FOR BNAB GENERATION
Recipient: DANA-FARBER CANCER INSTITUTE, 44 BINNEY STREET, BOSTON, MA, 021156013Award Number:R01AI084785Award Abstract:... virosome, including cholesterol, affect the membrane-embedded structure of the MPER, or its ability to undergo conformational changes upon antibody binding, will be assessed. In addition, lipid-enveloped nanoparticles as carriers of natively configured MPER segments with a bioresorbable poly (lactide-co-glycolide) (PLGA) core harboring invariant and promiscuous class II MHC molecule-binding epito ...
CFDA:93855 - Allergy and Infectious Diseases Research OPDIV:NIH Fiscal Year:2013 - 2009Award Amount:$2,887,263
ADJUVANTS AND VIROSOMAL VACCINES FOR THE ELDERLY
Recipient: UNIVERSITY OF BRITISH COLUMBIA, 2329 West Mall, VANCOUVER, B C, , 00000Award Number:U01AI074449Award Abstract:... adjuvants/virosomes in older adults. We will examine the effects of T/1/6 inflammatory cytokines directly on the function of aged CD4+ and CD8+ T cells in response to adjuvants added to killed virus or virosome vaccines. We will also examine the effects of adjuvants screened in Aim 1 on T cell responses to influenza vaccination, including CTL function. Our hypothesis is that these adjuva ...
CFDA:93855 - Allergy and Infectious Diseases Research OPDIV:NIH Fiscal Year:2011 - 2007Award Amount:$1,037,286
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
Recipient: UNIVERSITY OF LOUISIANA AT LAFAYETTE, P.O. BOX 43610, LAFAYETTE, LA, 70504Award Number:U19AI142636Award Abstract:... virosomes, enveloped virus-like particles that display on their surface elongated HIV gp41 peptides (virosome-P1) or recombinant truncated HIV gp41 (virosome-rgp41). Mymetics' Phase I clinical trial with virosome-P1 in healthy women showed safety and immunogenicity. Two independent nonhuman primate (NHP) studies demonstrated the safety and high efficacy of the combination of virosome-P1 + v ...
CFDA:93855 - Allergy and Infectious Diseases Research OPDIV:NIH Fiscal Year:2021 - 2020Award Amount:$2,781,288
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
Recipient: TEXAS BIOMEDICAL RESEARCH INSTITUTE, 7620 NORTHWEST LOOP 410, SAN ANTONIO, TX, 782275301Award Number:U19AI142636Award Abstract:... virosomes, enveloped virus-like particles that display on their surface elongated HIV gp41 peptides (virosome-P1) or recombinant truncated HIV gp41 (virosome-rgp41). Mymetics' Phase I clinical trial with virosome-P1 in healthy women showed safety and immunogenicity. Two independent nonhuman primate (NHP) studies demonstrated the safety and high efficacy of the combination of virosome-P1 + v ...
CFDA:93855 - Allergy and Infectious Diseases Research OPDIV: NIH Fiscal Year:2020 - 2019Award Amount:$1,014,631
https://taggs.hhs.gov/SearchSite
Human Vaccines Market to Grow Significantly by Forecast to 2026 | GlaxoSmithKline plc, Pfizer, Inc., Mymetics, Sanof
April 6, 2021
https://ksusentinel.com/2021/04/06/human-vaccines-market-to-grow-significantly-by-forecast-to-2026-glaxosmithkline-plc-pfizer-inc-mymetics-sanof/
Key roles of adjuvants in modern vaccines
Steven G Reed 1, Mark T Orr, Christopher B Fox
https://pubmed.ncbi.nlm.nih.gov/24309663/
Pam3CSK4
Synthetic triacylated lipoprotein; TLR2/TLR1 ligand
Catalog code: tlrl-pms
https://www.invivogen.com/pam3csk4
https://www.invivogen.com/sites/default/files/invivogen/products/files/pam3csk4_tds.pdf
Pfizer's top scientist says it is already working on a powder form of COVID-19 vaccine that could solve the problem of freezing the jab - and it could be available next year.
Powder vaccines, known as lyophilized formulations, can be reconstituted before injection, or sometimes administered through inhalation or intranasal vaccination.
https://www.dailymail.co.uk/news/article-8936107/Pfizers-scientist-says-working-powder-form-COVID-19-vaccine.html
How Sanofi COVID-19 Vaccine Candidates are Designed
www.sanofi.com › en › our-covid-19-vaccine
How Sanofi’s candidate COVID-19 recombinant protein vaccine is made. Sanofi’s candidate recombinant protein coronavirus vaccine, currently under development, uses the same technology as one of Sanofi’s seasonal influenza vaccines. The flu protein is simply switched to a protein from the surface of the SARS-CoV-2 virus–the spike protein.
https://www.sanofi.com/en/our-covid-19-vaccine-candidates/how-sanofi-covid-19-vaccine-candidates-are-designed
Study of Recombinant Influenza Vaccine Containing Different ...
clinicaltrials.gov › ct2 › show
Jun 30, 2020 · Individual HAI titer ratios against influenza H3 antigens not present in the vaccine formulations and individual SN titer ratio against each of the H3 antigens [ Time Frame: From Day 0 to Day 90 ] Titer ratio is calculated for the following time points: Day 7/Day 0, Day 28/Day 0, Day 90/Day 0
https://clinicaltrials.gov/ct2/show/NCT04451954
This was on one of his web pages!!
Claus-Michael Lehr
https://www.helmholtz-hzi.de/fileadmin/_processed_/a/6/csm_Fotolia_spray_Victor_Koldunov_5132860b04.jpg
The meeting will focus on predictive in vitro lung models designed for basic research, efficacy and toxicity testing. It aims to present the state-of-the-art in vitro lung models, and to map out the road for its future development and use.
Prof. Claus Michael Lehr (Saarland University) Catalent to :)
https://www.epithelix.com/events/live-2021
the current study illustrates the feasibility and practicality of employing liposomes as a means to achieve 25(OH)D lung deposition. 25(OH)D-loaded liposomes further demonstrated promising effects regarding prevention of Pseudomonas infection in human bronchial epithelial cells.
Claus Michael Lehar
https://pubmed.ncbi.nlm.nih.gov/27888144/
Researchers develop eleven SARS-CoV-2 RBD nanobodies using ...
www.news-medical.net › news › 20210427
17 hours ago · Dr. Ramya Dwivedi. Ramya has a Ph.D. in Biotechnology from the National Chemical Laboratories (CSIR-NCL), in Pune. Her work consisted of functionalizing nanoparticles with different molecules of ...
Researchers develop eleven SARS-CoV-2 RBD nanobodies using computational design
https://www.news-medical.net/news/20210427/Researchers-develop-eleven-SARS-CoV-2-RBD-nanobodies-using-computational-design.aspx
TRANSVAC2 CALL FOR TRAINING “ADJUVANTS AND VACCINE FORMULATION”
Technology platform Vaccines
THEORETICAL COURSE ON ADJUVANTS AND VACCINE FORMULATION
25-28 March 2019, Geneva, Switzerland.
https://eatris.eu/insights/transvac2-call-training-adjuvants-vaccine-formulation/